Amneal Pharmaceuticals, Inc.

Annual Trend FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash and cash equivalents $213.4m $151.2m $341.4m $247.8m $26.0m $91.5m $110.6m $282.0m
Receivables $481.5m $604.4m $638.9m $662.6m $741.8m $614.7m $776.2m $895.6m
Inventories $457.2m $381.1m $490.6m $489.4m $530.7m $581.4m $612.5m $606.3m
Prepaid expenses and other current assets $128.3m $70.2m $73.5m $110.2m $103.6m $82.7m $80.7m $98.4m
Total current assets $1.3b $1.2b $1.6b $1.5b $1.4b $1.4b $1.6b $1.9b
Property, plant and equipment, net $544.1m $478.0m $477.8m $514.2m $469.8m $447.6m $424.9m $442.9m
Goodwill $426.2m $419.5m $522.8m $593.0m $598.9m $598.6m $597.4m $595.5m
Intangible assets, net $1.7b $1.4b $1.3b $1.2b $1.1b $890.4m $732.4m $563.5m
Operating lease right-of-use assets $0 $69.9m $58.7m $60.4m $56.1m $43.3m $42.4m $54.0m
Financing lease right of use assets $0 $61.3m $58.7m $64.5m $63.4m $59.3m $56.4m $53.3m
Other assets $67.6m $44.3m $31.9m $20.6m $103.2m $55.5m $60.1m $57.8m
Restricted cash $5.4m $1.6m $5.7m $8.9m $9.3m $7.6m $7.9m $28.8m
Payable $514.4m $507.5m $613.7m $583.3m $538.2m $542.0m $757.8m $816.8m
Current portion of liabilities for legal matters $58.0m $107.5m $77.0m $31.8m $43.3m
Revolving credit facility $0 $60.0m $179.0m $100.0m $0
Current portion of operating lease liabilities $0 $14.4m $9.3m $12.3m $11.2m $12.0m $12.8m $11.4m
Current portion of financing lease liabilities $3.0m $3.1m $3.5m $2.5m $3.2m $3.4m
Operating lease liabilities $0 $58.6m $53.2m $51.7m $48.0m $36.9m $34.2m $47.4m
Financing lease liabilities $0 $61.5m $60.2m $60.3m $60.8m $58.6m $56.9m $54.9m
Liabilities for legal matters - long term $316k $85.5m $71.8m
Redeemable non-controlling interests $0 $11.8m $16.9m $24.9m $41.3m $65.0m $77.3m
Non-controlling interests $391.6m $114.8m $41.7m $6.6m ($114.4m) $230k ($245k) ($535k)
Total long-term liabilities $2.9b $2.8b $3.0b $2.9b $2.8b $2.6b $2.4b $2.8b
Total Amneal Pharmaceuticals, Inc. stockholders’ deficiency $504.8m $232.0m $303.3m $360.3m $298.4m $19.8m ($109.3m) ($70.8m)
Total stockholders’ deficiency $896.4m $346.8m $344.9m $367.0m $184.0m $20.0m ($109.5m) ($71.3m)
Total assets $4.4b $3.7b $4.0b $3.9b $3.8b $3.5b $3.5b $3.7b
Total liabilities and stockholders’ deficiency $4.4b $3.7b $4.0b $3.9b $3.8b $3.5b $3.5b $3.7b
Current portion of long-term debt, net $21.4m $21.5m $44.2m $30.6m $30.0m $34.1m $224.2m $6.8m
Total current liabilities $553.9m $550.4m $676.9m $677.2m $752.8m $846.6m $1.1b $881.6m
Long-term debt, net $2.6b $2.6b $2.7b $2.7b $2.6b $2.4b $2.2b $2.6b
Other long-term liabilities $38.8m $39.6m $85.7m $38.9m $87.5m $41.8m $77.8m $51.4m
Commitments and contingencies (Notes 4, 19 and 22) $0 $0
Preferred stock, $0.01 par value, 2,000 shares authorized at December 31, 2025 and 2024; none issued at both December 31, 2025 and 2024 $0 $0 $0 $0 $0 $0 $0 $0
Common stock $3.0m $3.0m $3.0m $3.0m $3.0m $3.1m $3.1m $3.1m
Additional paid-in capital $530.4m $607.0m $628.4m $658.4m $691.6m $539.2m $560.2m $571.8m
Stockholders’ accumulated deficit ($20.9m) ($377.9m) ($286.8m) ($276.2m) ($406.2m) ($490.2m) ($607.1m) ($535.0m)
Accumulated other comprehensive loss ($7.8m) ($68k) ($41.3m) ($24.8m) $9.9m ($32.3m) ($65.5m) ($110.7m)

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.